Venetoclax plus intensive chemo for AML subtypes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 60 years old.
- You must have a diagnosis of acute myeloid leukemia (AML) or a related condition.
- Your overall health (performance status) must be good enough for daily activities (ECOG 0-2).
- Your liver, kidney, and heart function must be within safe limits, as shown by blood tests and an echocardiogram.
- You cannot have certain types of leukemia (APL or BCR-ABL-positive) or have had prior AML treatment (except low-dose therapy to lower blast counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding venetoclax (a targeted drug) to standard chemotherapy helps patients with acute myeloid leukemia (a blood cancer) who have responded well to initial treatment stay cancer-free longer. You would receive the combination or standard therapy alone to see which works better.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.